Molecular Partners AG (SWX:MOLN)
Switzerland · Delayed Price · Currency is CHF 3.050
-0.070 (-2.24%)
Apr 1, 2026, 5:30 PM CET
Molecular Partners AG Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
134
Market Cap
114.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | 2.49M | 9.37% |
| Dec 31, 2014 | 26.63M | -5.79M | -17.87% |
| Dec 31, 2013 | 32.42M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Basilea Pharmaceutica AG | 232.38M |
| Idorsia | 220.58M |
| Santhera Pharmaceuticals Holding AG | 49.02M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Xlife Sciences AG | 839.38K |
| Addex Therapeutics | 158.54K |
Molecular Partners AG News
- 9 days ago - Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - GlobeNewsWire
- 13 days ago - Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes - GlobeNewsWire
- 15 days ago - Molecular Partners to Hold Three Poster Presentations at AACR 2026 - GlobeNewsWire
- 20 days ago - Molecular Partners Reports Highlights and Financial Results for Full Year 2025 - GlobeNewsWire
- 4 weeks ago - Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results - GlobeNewsWire
- 2 months ago - Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript - Seeking Alpha
- 2 months ago - Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 - GlobeNewsWire
- 2 months ago - Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha